Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Oral Tecovirimat for the Treatment of Smallpox.

Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, Lovejoy C, Meara I, Long P, Hruby DE.

N Engl J Med. 2018 Jul 5;379(1):44-53. doi: 10.1056/NEJMoa1705688.

2.

Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection.

Amantana A, Chen Y, Tyavanagimatt SR, Jones KF, Jordan R, Chinsangaram J, Bolken TC, Leeds JM, Hruby DE.

PLoS One. 2013 Apr 18;8(4):e61514. doi: 10.1371/journal.pone.0061514. Print 2013.

3.

Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans.

Leeds JM, Fenneteau F, Gosselin NH, Mouksassi MS, Kassir N, Marier JF, Chen Y, Grosenbach D, Frimm AE, Honeychurch KM, Chinsangaram J, Tyavanagimatt SR, Hruby DE, Jordan R.

Antimicrob Agents Chemother. 2013 Mar;57(3):1136-43. doi: 10.1128/AAC.00959-12. Epub 2012 Dec 17.

4.

Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers.

Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF, Jordan R, Marbury T, Ruckle J, Mee-Lee D, Ross E, Lichtenstein I, Pickens M, Corrado M, Clarke JM, Frimm AM, Hruby DE.

Antimicrob Agents Chemother. 2012 Sep;56(9):4900-5. doi: 10.1128/AAC.00904-12. Epub 2012 Jul 9.

5.

Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers.

Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Bolken TC, Jordan R, Jones KF, Marbury T, Lichtenstein I, Pickens M, Corrado M, Landis P, Clarke JM, Frimm AM, Hruby DE.

Antimicrob Agents Chemother. 2012 Jul;56(7):3582-6. doi: 10.1128/AAC.06090-11. Epub 2012 Apr 23.

6.

Evaluation of Lassa antiviral compound ST-193 in a guinea pig model.

Cashman KA, Smith MA, Twenhafel NA, Larson RA, Jones KF, Allen RD 3rd, Dai D, Chinsangaram J, Bolken TC, Hruby DE, Amberg SM, Hensley LE, Guttieri MC.

Antiviral Res. 2011 Apr;90(1):70-9. doi: 10.1016/j.antiviral.2011.02.012. Epub 2011 Mar 1.

7.

Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.

Jordan R, Chinsangaram J, Bolken TC, Tyavanagimatt SR, Tien D, Jones KF, Frimm A, Corrado ML, Pickens M, Landis P, Clarke J, Marbury TC, Hruby DE.

Antimicrob Agents Chemother. 2010 Jun;54(6):2560-6. doi: 10.1128/AAC.01689-09. Epub 2010 Apr 12.

8.

ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.

Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, Mucker E, Shamblin J, Bolken TC, Wlazlowski C, Johnson W, Chapman J, Twenhafel N, Tyavanagimatt S, Amantana A, Chinsangaram J, Hruby DE, Huggins J.

Antimicrob Agents Chemother. 2009 May;53(5):1817-22. doi: 10.1128/AAC.01596-08. Epub 2009 Feb 17.

9.

Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.

Palena C, Foon KA, Panicali D, Yafal AG, Chinsangaram J, Hodge JW, Schlom J, Tsang KY.

Blood. 2005 Nov 15;106(10):3515-23. Epub 2005 Aug 4.

10.

Engineering better vaccines for foot-and-mouth disease.

Mason PW, Chinsangaram J, Moraes MP, Mayr GA, Grubman MJ.

Dev Biol (Basel). 2003;114:79-88.

PMID:
14677679
12.
14.

Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs.

Mayr GA, O'Donnell V, Chinsangaram J, Mason PW, Grubman MJ.

Vaccine. 2001 Feb 28;19(15-16):2152-62.

PMID:
11228388
15.
16.
18.

Development of DNA vaccines for foot-and-mouth disease, evaluation of vaccines encoding replicating and non-replicating nucleic acids in swine.

Beard C, Ward G, Rieder E, Chinsangaram J, Grubman MJ, Mason PW.

J Biotechnol. 1999 Aug 20;73(2-3):243-9. Review.

PMID:
10486933
19.

Construction and evaluation of an attenuated vaccine for foot-and-mouth disease: difficulty adapting the leader proteinase-deleted strategy to the serotype O1 virus.

Almeida MR, Rieder E, Chinsangaram J, Ward G, Beard C, Grubman MJ, Mason PW.

Virus Res. 1998 May;55(1):49-60.

PMID:
9712511
20.
21.

Antibody response in mice inoculated with DNA expressing foot-and-mouth disease virus capsid proteins.

Chinsangaram J, Beard C, Mason PW, Zellner MK, Ward G, Grubman MJ.

J Virol. 1998 May;72(5):4454-7.

22.

Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate.

Mason PW, Piccone ME, Mckenna TS, Chinsangaram J, Grubman MJ.

Virology. 1997 Jan 6;227(1):96-102.

23.

PCR detection of acute Ehrlichia canis infection in dogs.

McBride JW, Corstvet RE, Gaunt SD, Chinsangaram J, Akita GY, Osburn BI.

J Vet Diagn Invest. 1996 Oct;8(4):441-7.

PMID:
8953528
24.

Prevalence of group A and group B rotaviruses in the feces of neonatal dairy calves from California.

Chinsangaram J, Schore CE, Guterbock W, Weaver LD, Osburn BI.

Comp Immunol Microbiol Infect Dis. 1995 Feb;18(2):93-103.

PMID:
7621673
25.

Detection of bovine group B rotaviruses in feces by polymerase chain reaction.

Chinsangaram J, Akita GY, Osburn BI.

J Vet Diagn Invest. 1994 Jul;6(3):302-7.

PMID:
7948199
26.

PCR detection of group A bovine rotaviruses in feces.

Chinsangaram J, Akita GY, Castro AE, Osburn BI.

J Vet Diagn Invest. 1993 Oct;5(4):516-21.

PMID:
8286448
27.

Detection of bluetongue virus serogroup by polymerase chain reaction.

Akita GY, Chinsangaram J, Osburn BI, Ianconescu M, Kaufman R.

J Vet Diagn Invest. 1992 Oct;4(4):400-5.

PMID:
1281002
28.

Detection of bluetongue virus using a cDNA probe derived from genome segment 4 of bluetongue virus serotype 2.

Chinsangaram J, Hammami S, Osburn BI.

J Vet Diagn Invest. 1992 Jan;4(1):8-12.

PMID:
1313308

Supplemental Content

Loading ...
Support Center